Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals

[1]  M. Dowty,et al.  Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites , 2021, Journal of clinical pharmacology.

[2]  G. Chan,et al.  15433 Assessment of cytochrome P450 3A inhibition and induction of abrocitinib: Midazolam drug-drug interaction (DDI) study and oral contraceptive DDI study , 2020 .

[3]  C. Flohr,et al.  Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial , 2020, The Lancet.

[4]  J. Silverberg,et al.  Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis , 2020, JAMA dermatology.

[5]  J. Bauman,et al.  P190 - The effect of CYP2C9 and CYP2C19 genotype on the pharmacokinetics of PF 04965842, A JAK1 inhibitor in clinical development , 2020 .

[6]  M. Hegen,et al.  Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition , 2019, Pharmacology research & perspectives.

[7]  E. Peeva,et al.  Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis , 2019, JAMA dermatology.

[8]  S. Tarabar,et al.  Evaluation of a Janus kinase 1 inhibitor, PF‐04965842, in healthy subjects: A phase 1, randomized, placebo‐controlled, dose‐escalation study , 2018, British journal of clinical pharmacology.

[9]  Mark J. Mitton-Fry,et al.  Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. , 2018, Journal of medicinal chemistry.

[10]  DIFLUCAN® (Fluconazole Tablets) (Fluconazole for Oral Suspension) , 2018 .

[11]  P. Diderichsen,et al.  Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection , 2015, Clinical Pharmacokinetics.

[12]  Philip Timmerman,et al.  Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. , 2009, Chemical research in toxicology.

[13]  M. Leggas,et al.  Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. , 2007, Clinical therapeutics.

[14]  A. Avenoso,et al.  Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone , 1999, Psychopharmacology.

[15]  L. Bertilsson,et al.  Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine , 1998, Clinical pharmacology and therapeutics.